Sarcoptic mange may cause severe clinical disease in alpacas (Vicugna pacos), and treatment outcomes with commonly used acaricides can be variable. Fluralaner, an isoxazoline drug licensed as an insecticide and acaricide in different species, has been reported as a promising off-label option in alpacas, but pharmacokinetic data and evidence from herd settings are lacking. This study aims to define the pharmacokinetic profile of orally administered fluralaner in alpacas naturally affected by sarcoptic mange. A herd of seven adult female alpacas with clinical mange received a single oral dose of fluralaner at 5.2 mg/kg. Serial blood sampling from pre-treatment to 60 days post-administration was performed; then, serum fluralaner concentrations were quantified by a validated UPLC–HRMS-MS/MS method and analyzed using a non-compartmental approach for pharmacokinetic profile determination. Fluralaner showed prolonged systemic exposure, although marked inter-individual variability was observed. Mean Cmax was 498.18 ± 302.02 ng/mL, reached at 1.6 ± 0.5 days, with an AUClast of 3323.19 ± 1866.60 ng × day/mL and an elimination half-life of 6.8 ± 2.8 days. Quantifiable concentrations persisted for 35.0 ± 11.2 days on average. No adverse effects were observed, and all animals showed progressive clinical improvement. The findings indicate that a single oral dose of fluralaner provides sustained systemic exposure in alpacas, while further studies are warranted to refine the dosing regimen and to assess its clinical efficacy under herd conditions.

Pharmacokinetics of orally administered fluralaner in alpacas (Vicugna pacos) affected by sarcoptic mange / F. Di Cesare, L.U.. - In: ANIMALS. - ISSN 2076-2615. - 16:21(2026 Nov), pp. 3399.1-3399.13. [10.3390/ani16213399]

Pharmacokinetics of orally administered fluralaner in alpacas (Vicugna pacos) affected by sarcoptic mange

F. Di Cesare
Primo
;
L. Ucci
Secondo
;
P. Cagnardi
;
A.L. Gazzonis;S.A.G. Zanzani;R. Pavlovic;R.E. Villa;S. Draghi;F. Arioli;G. Sala
Ultimo
2026

Abstract

Sarcoptic mange may cause severe clinical disease in alpacas (Vicugna pacos), and treatment outcomes with commonly used acaricides can be variable. Fluralaner, an isoxazoline drug licensed as an insecticide and acaricide in different species, has been reported as a promising off-label option in alpacas, but pharmacokinetic data and evidence from herd settings are lacking. This study aims to define the pharmacokinetic profile of orally administered fluralaner in alpacas naturally affected by sarcoptic mange. A herd of seven adult female alpacas with clinical mange received a single oral dose of fluralaner at 5.2 mg/kg. Serial blood sampling from pre-treatment to 60 days post-administration was performed; then, serum fluralaner concentrations were quantified by a validated UPLC–HRMS-MS/MS method and analyzed using a non-compartmental approach for pharmacokinetic profile determination. Fluralaner showed prolonged systemic exposure, although marked inter-individual variability was observed. Mean Cmax was 498.18 ± 302.02 ng/mL, reached at 1.6 ± 0.5 days, with an AUClast of 3323.19 ± 1866.60 ng × day/mL and an elimination half-life of 6.8 ± 2.8 days. Quantifiable concentrations persisted for 35.0 ± 11.2 days on average. No adverse effects were observed, and all animals showed progressive clinical improvement. The findings indicate that a single oral dose of fluralaner provides sustained systemic exposure in alpacas, while further studies are warranted to refine the dosing regimen and to assess its clinical efficacy under herd conditions.
alpacas; ectoparasiticides; fluralaner; isoxazolines; mange; pharmacokinetics; Sarcoptes scabiei; South American camelids
Settore MVET-04/A - Farmacologia e tossicologia veterinaria
Settore MVET-04/B - Clinica medica veterinaria
Settore MVET-03/B - Parassitologia e malattie parassitarie degli animali e dell'uomo
nov-2026
28-ott-2026
Article (author)
File in questo prodotto:
File Dimensione Formato  
Di Cesare et al., 2026_PK Oral fluralaner in alpacas.pdf

accesso aperto

Descrizione: Articolo nella sua versione definitiva PDF
Tipologia: Publisher's version/PDF
Licenza: Creative commons
Dimensione 1.33 MB
Formato Adobe PDF
1.33 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I metadati presenti in AIR sono rilasciati con licenza CCO mentre i file delle pubblicazioni sono rilasciati con licenza CC BY-SA, salvo diversa indicazione. In caso di violazione di copyright, contattare l'assistenza di AIR

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1276276
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex 0
social impact